Information Provided By: 
Fly News Breaks for April 22, 2019
ZYNE
Apr 22, 2019 | 07:10 EDT
Canaccord analyst Sumant Kulkarni assumed coverage of Zynerba Pharmaceuticals with a Buy rating and $18 price target. In a research note to investors, Kulkarni says he believes Zynerba, with Zygel's multiple shots on goal, presents significant opportunity for risk-tolerant investors heading into key events, including data for an open-label Phase 2 trial in developmental and epileptic encephalopathies in the third quarter of 2019, and data for a trial for Fragile X syndrome in the second half of the year.
News For ZYNE From the Last 2 Days
There are no results for your query ZYNE
